Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study using pacritinib for patients with histologically
confirmed prostate adenocarcinoma, status post definitive treatment and biochemical
recurrence.